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Introduction
MCC (EC 6.4.1.4) is a biotin-dependent carboxylase that
catalyzes the fourth step in the leucine catabolic path-
way. Isolated, biotin-resistant MCC deficiency (also
known as methylcrotonylglycinuria [MIM 210200]) is
inherited as an autosomal recessive trait (1). The clinical
phenotype is highly variable: some patients present in
the neonatal period with seizures and muscular hypoto-
nia (2, 3); others are asymptomatic women identified
only by detection of abnormal metabolites in the neona-
tal screening samples of their healthy babies (4). There is
a characteristic organic aciduria with massive excretion
of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine,
usually in combination with a severe secondary carnitine
deficiency. MCC activity in extracts of cultured fibrob-
lasts of patients is usually less than 2% of control. No
correlation between the level of residual enzyme activity
and clinical presentation has been observed.
Tandem mass spectrometry (MS/MS), recently intro-
duced for newborn screening, provides for the first time
to our knowledge a way to detect a large variety of organ-
ic acidurias including MCC deficiency (5). Surprisingly,
MCC deficiency appears to be the most frequent organ-
ic aciduria detected in MS/MS screening programs in
North America (4, 6, 7), Europe (8), and Australia (9),
with an overall frequency of approximately 1 in 50,000.
MCC is a member of the family of biotin-dependent
carboxylases, a group of enzymes with diverse meta-
bolic functions but common structural features (10,
11). Members of this family have three structurally con-
served functional domains: the biotin carboxyl carrier
domain, which carries the biotin prosthetic group; the
biotin carboxylation domain, which catalyzes the car-
boxylation of biotin; and the carboxyltransferase
domain, which catalyzes the transfer of a carboxyl
group from carboxybiotin to the organic substrate spe-
cific for each carboxylase (10, 12). In addition to MCC,
there are three other biotin-dependent carboxylases in
humans: propionyl-CoA carboxylase (PCC), pyruvate
carboxylase (PC), and acetyl-CoA carboxylase (ACC)
(10, 11). The genes for all human carboxylases except
MCC have been cloned and characterized (13–15).
MCC carboxylates 3-methylcrotonyl-CoA at the 4-
carbon to form 3-methylglutaconyl-CoA (Figure 1) (1).
The reaction uses ATP and bicarbonate and is
reversible. Bovine MCC has an approximate size of 835
kDa and appears to comprise six heterodimers (αβ)6
(16). Like PCC, MCC has a larger α subunit, which
covalently binds biotin, and a smaller β subunit (13).
MCC is predominantly localized to the inner mem-
brane of mitochondria and is known to be highly
expressed in kidney and liver (1). cDNAs encoding both
subunits of MCC recently have been cloned in Ara-
bidopsis thaliana and other plants (17, 18).
Here we report cloning of human MCCA and MCCB
cDNAs, confirmation of their identity by biochemical
and molecular studies, and identification of mutations
in MCC-deficient patients.
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Isolated biotin-resistant 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal
recessive disorder of leucine catabolism that appears to be the most frequent organic aciduria
detected in tandem mass spectrometry–based neonatal screening programs. The phenotype is
variable, ranging from neonatal onset with severe neurological involvement to asymptomatic
adults. MCC is a heteromeric mitochondrial enzyme composed of biotin-containing α subunits
and smaller β subunits. Here, we report cloning of MCCA and MCCB cDNAs and the organiza-
tion of their structural genes. We show that a series of 14 MCC-deficient probands defines two
complementation groups, CG1 and 2, resulting from mutations in MCCB and MCCA, respective-
ly. We identify five MCCA and nine MCCB mutant alleles and show that missense mutations in
each result in loss of function.
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Methods
Patients, complementation analysis, and MCC assay
This study includes 16 MCC-deficient probands, all of
whom had the diagnostic pattern of organic acid excre-
tion and less than 10% MCC activity in extracts of cul-
tured skin fibroblasts. Clinical and biochemical data of
ten patients have been reported in the literature: 001 (3),
002 (2), 003 (19), 004 (20), 006 (21), 007 (22), 010 (23),
011 (24), 012 (25), and 016 (4). Fibroblasts or DNA of
the remaining patients were referred by B.T. Poll-The
(patient 005), H.G. Koch (patient 008), J. Smeitink
(patient 009), U. von Döbeln (patient 013), R.D. De Kre-
mer Dodelson (patient 014), and D.H. Morton (patient
015). Skin fibroblasts were cultured in Eagle’s minimal
essential medium (Life Technologies Inc., Rockville,
Maryland, USA) supplemented with 2 mmol/l L-gluta-
mine and 10% FCS. Complementation analysis was
modified from that described by Wolf et al. (26). Briefly,
we produced heterokaryons by a 90- or 120-second
treatment with 40% PEG harvested the cells 3 days later
and measured MCC activity as described previously (3,
27). MCC activity in cultures of mixed but unfused cells
was subtracted as blank and self fusions were included
as a negative control.
Expression of biotin-containing proteins in
fibroblasts
We harvested cultured fibroblasts by trypsinization,
disrupted the washed cells by homogenization, har-
vested the mitochondria by differential centrifugation
(28), suspended them in SDS-buffer (50 mM Tris-
acetate, 1% SDS [wt/vol], 10 mM DTT, 0.02% [wt/vol]
bromphenol blue), and dissolved the proteins by boil-
ing for 5 minutes. The cellular proteins were separated
by SDS-PAGE, and the biotin-containing proteins were
detected with an avidin alkaline phosphatase conjugate
(avidin-AP, 1:8,000; Bio-Rad Laboratories AG, Glat-
tbrugg, Switzerland).
Fibroblasts of an unaffected control, a patient with
isolated PC deficiency, and a patient with isolated
PCCα deficiency were used to confirm the identity of
the protein bands.
cDNA cloning, sequence analysis, 
and chromosome mapping
We obtained two mouse (AI317324 and AI117072) and
two human (AA134548 and AA101775) MCCA EST
clones, and one human MCCB (AI564487) EST clone
from the IMAGE consortium (Genome Systems Inc.,
St. Louis, Missouri, USA) and sequenced both strands
with an ABI 377 automated sequencer. To design
primers corresponding to the 5′ UTR of our putative
MCCA, we used the sequence of the MCCA EST clone
AA337013 (not available commercially). We used
primers DV4418 (sense, 5′-GACGCAGCTGCCTCTG TAC)
and DV4417 (sense, 5′-TGGCCGGGCTCCAGGGACATG),
complementary to the 5′UTR, and DV4446 (antisense,
5′-AACTGCTCTTTATGAGACCCC), complementary to the
3′ UTR, to amplify full-length human MCCA from a
human retina cDNA library (29); and primers DV4496
(sense, 5′-AGGACCTGAGCTCAGCTTCC) and DV4497
(sense, 5′-TCGGTGCCCGCCGCCATG), complementary
to the 5′ UTR, and DV 4495 (antisense, 5′-ACTG-
TAACAGCCTCATGTTCG), complementary to the 3′
UTR, to amplify full-length human MCCB from the
same human retina cDNA library (29). We gel-purified
the PCR products and sequenced them directly. The
sequence alignments were prepared with MegAlign
(DNASTAR Inc., Madison, Wisconsin, USA).
We mapped HsMCCA using the Genebridge 4 radia-
tion hybrid panel (Research Genetics Inc., Huntsville,
Alabama, USA) using primers DV4621 (sense, 5′-
TTTGTCGTCTCAGACTCGATG) and DV4740 (antisense,
5′-AGTCAGAAAAATAAGGCCAACC) corresponding to 5′
flanking intronic sequence of exon 6 and 3′ flanking
intronic sequence of exon 7.
Isolation and mass spectrometry analysis of biotin-
containing proteins
Enrichment for biotin-containing proteins. We homogenized
0.32 g of flash frozen male mouse kidney in 1.5 ml
buffer A (100 mM Tris-HCl [pH 7.4], 20 mM DTT, 1
mM EDTA, 0.1% (vol/vol) Triton X-100, 20% (vol/vol)
glycerol, 1 µM DMSF, 1 tablet cocktail protease
inhibitor (Boehringer-Mannheim) and centrifuged the
homogenate at 20,000 g for 20 minutes at 4°C. PEG
was added to the supernatant to a final concentration
of 16% (wt/vol), and the mixture was centrifuged at
20,000 g for 30 minutes at 4°C. The pellet was resus-
pended in 1 ml of buffer A, approximately 3 × 108 pre-
washed M280 streptavidin Dynabeads (Dynal Inc.,
Lake Success, New York, USA) were added, and the slur-
ry mixed by rotating for 1 hour at 4°C. We washed the
beads five times with buffer B (0.25 M KCl in buffer A),
resuspended them in 200 µl of XI protein loading
buffer, boiled for 5 minutes, and placed the solution on
ice. We loaded 25 µl in each lane of a 10% polyacry-
lamide gel and stained the separated proteins with
Coomassie Brilliant blue R250.
S-carboxymethylation and proteolytic digestion. We per-
formed in gel digestion of the proteins using the
Coomassie blue–stained SDS-polyacrylamide gels
according to Williams et al. (30) with the following
modifications. Cystines were modified by car-
boxymethylation as described elsewhere (31). After
rehydrating gel pieces with 5 ng/µl TPCK-treated
trypsin in 1% acetic acid, excess trypsin solution was
removed and the gel piece was covered with 2 gel vol-
umes of 200 mM NH4HCO3 (pH 8), at 37°C for 48
hours. The resulting tryptic peptides were extracted
from the gel piece with 60% acetonitrile in 0.1% TFA
and concentrated by drying.
Mass spectrometry analysis. Tryptic peptides were resus-
pended in 1% acetic acid and loaded into a fused silica
capillary column (75 µm inner diameter) packed with
10 cm of 5 µm C18 reverse-phase resin (YMC Inc.,
Atlanta, Georgia, USA) as described elsewhere (32). A
30-minute, 1.5–70% methanol gradient in 1% acetic
acid was applied to the column at flow rates of
250–300 nl/min. Eluting peptides were electrosprayed
directly into a Finnigan LCQ atmospheric pressure
ionization quadrupole ion trap mass spectrometer
(ThermoQuest Corp., San Jose, California, USA). Pos-
itive-ion mass spectra were obtained at using XCal-
ibur software (ThermoQuest Corp.). Peptides were
fragmented by a 35% collision energy using a two-
atomic-mass-unit isolation width. Fragmentation
data were screened against the protein.nrdb.Z data-
base from the Frederick Biomedical Supercomputing
Center (ftp://ftp.ncifcrf.gov/pub/nonredun/) using the
SEQUEST Browser (33) (ThermoQuest Corp.).
Mutation analysis by RT-PCR and genomic PCR
We extracted RNA and genomic DNA from cultured
skin fibroblasts and/or blood using the Puregene RNA
and DNA isolation kits (Gentra Systems, Minneapolis,
Minnesota, USA) and performed RT-PCR using 5–10
µg fibroblast RNA and a cDNA cycle kit (Invitrogen
Corp., Carlsbad, California, USA) following the manu-
facturers’ recommendations. We generated first-strand
cDNA with primers DV4403 (antisense, 5′-GACC-
CAAATGCATGATTCTCC), complementary to sequence
in the MCCA 3′ UTR region, and DV 4506 (antisense,
5′-GGTAGAAAAGTACAA TGCACAG), complementary to
sequence in the MCCB 3′ UTR region. We then ampli-
fied first-strand MCCA cDNA with primers DV4418
and DV4446 to generate a 2,326-bp fragment (–51 to
+2275, where +1 is the A of the initiation methionine
codon); and we amplified first-strand MCCB cDNA
with primers DV4496 and DV 4495 to generate a 1,923-
bp fragment (–99 to +1824). In some instances, when
the amount of amplified product was inadequate, we
went through a second round of PCR with nested
primers DV4417 and DV4497. We gel-purified the PCR
products and sequenced them directly.
To confirm mutations identified in RT-PCR products,
we amplified a genomic fragment containing the corre-
sponding exon using flanking intronic primers and
sequenced the PCR product directly. In the compound
heterozygous patients in whom we identified only one
of two alleles in RT-PCR products, we amplified and
sequenced all exons and flanking intronic sequences.
All PCR reactions (50 µl) contained primers (100 ng
each), 1× standard PCR buffer (Life Technologies Inc.),
dNTPs (200 µM), and Taq polymerase (2.5 U; Life Tech-
nologies Inc.). The sequences of all primers are available
upon request.
To survey a control population for the identified mis-
sense mutations, we amplified the relevant exon from
genomic DNA and performed allele-specific oligonu-
cleotide analysis as described previously (34).
Construction of wild-type and mutant human
MCCA/B expression vectors
We TA cloned the full-length human MCCA (–51 to
+2275) and MCCB (–99 to +1824) cDNAs into pCR
Blunt II TOPO (Invitrogen Corp.). To introduce the
MCCA mutations R385S, A289V, and L437P, we har-
vested an 896-bp ACCI fragment from RT-PCR–ampli-
fied patient cDNA and subcloned this fragment into
the pMCCA-TOPO construct. We then transferred the
wild-type and mutant MCCA constructs into a mam-
malian expression vector (pTracer-CMV2; Invitrogen-
Corp.) at the EcoR I site. This vector contains a green
fluorescent protein (GFP) gene fused to the Zeocin
resistance gene. Similarly, to introduce the MCCB mis-
sense mutation E99Q, we harvested a 193-bp EcoN
I/BstE II fragment from RT-PCR amplified patient
cDNA, subcloned this fragment into the pMCCB-
TOPO construct and then transferred the wild-type
and mutant constructs into pTracer-CMV2. To intro-
duce the MCCB missense mutations S173L, V339M,
R155C, P310R and R193C, we harvested a 965-bp BstE
II/Sfi I fragment from RT-PCR–amplified patient
cDNA and subcloned this fragment directly into
MCCB-pTracer-CMV2. We sequenced all constructs in
both directions to validate the sequences.
Transfections
We transformed primary fibroblasts from proband 010
(homozygous for MCCA Q421fs(+1), from proband
001 (homozygous for MCCB S173L), and from a con-
trol as described previously (34). For expression stud-
ies, we electroporated the indicated constructs into
transformed cells as described elsewhere (34). We har-
vested the cells after 72 hours and measured MCC and
PCC activity radioisotopically as described previously
(27). Our standard MCC assay enables us to reliably
detect activity as low as 5–10 pmol/min/mg protein. All
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Figure 1
The MCC-catalyzed reaction and its position in the leucine catabol-
ic pathway. The dashed arrow indicates the metabolites that accu-
mulate due to deficiency of MCC.
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transfections were in duplicates. Transformed fibrob-
lasts from an unaffected individual were used as con-
trol. Transfection efficiency was assessed by coexpress-
ing GFP in the same construct.
Results
Genetic complementation and assignment to MCCA
or MCCB
As an initial step in defining the molecular basis of
MCC deficiency, we performed biochemical and
somatic cell genetic studies with fibroblasts from 14
MCC-deficient probands. Using restoration of MCC
activity in PEG-induced heterokaryons of fibroblasts
as an end point, we defined two complementation
groups (CGs), one comprising eight probands (MCC-
CG1, 001-008) and the other, six probands (MCC-
CG2, 009-014) (data available upon request). Given
that MCC is composed of αβ heteromers, we antici-
pated that the two CGs likely corresponded to muta-
tions in genes encoding the α and β subunits of MCC
(encoded by MCCA and MCCB, respectively).
To investigate the complementation phenotype at
the protein level, we examined the expression of the
MCCα subunit using the covalently bound biotin as a
tag in fibroblasts of five of six CG2 and in all of the
eight CG1 probands (Figure 2). In CG2, MCCα was
not detected in four of five probands, whereas in the
remaining CG2 cell line (proband 011), the MCCα
band was at least as intense as in controls (Figure 2).
In all the CG1 cell extracts, MCCα was reduced but
present. These results suggested that MCC-CG2 is
caused by mutations in MCCA and, by exclusion,
MCC-CG1, by mutations in MCCB.
Identification of mammalian candidate MCCA and
MCCB cDNAs
Database search. We used the amino acid sequences of
A. thaliana MCCA and MCCB (17, 18) and the
TBLASTN algorithm to probe the public EST data-
bases to identify murine and human cDNAs encoding
candidate MCCAs and MCCBs. We used the murine
candidates to assemble full-length mouse putative
MCCA cDNA (GenBank accession number: MmMC-
CA: AF310338) and the human candidate ESTs to
design primers corresponding to the predicted 5′ and
3′ UTR of the putative human MCCA and MCCB
cDNAs. Using these primer pairs, we amplified a sin-
gle fragment of the predicted size for both MCCA and
MCCB from a human retina cDNA library (29). Gen-
Bank accession numbers: HsMCCA: AF310339. HsM-
CCB: AF301000. We used additional ESTs to extend
the 5′ and 3′ UTR sequences. The sequence of the
human MCCA candidate has 57 bp of 5′ UTR, a
2,175-bp ORF, and 222 bp of 3′ UTR extending to a
polyadenylation signal (AAUAAA). The murine can-
didate MCCA cDNA has 42 bp of 5′ UTR, a 2,151-bp
ORF, and 190 bp of 3′ UTR extending to a probable
polyadenylation signal (AUAAA). The sequence of the
amplified human MCCB candidate has 99 bp of 5′
UTR, a 1,689-bp ORF, and 540 bp of 5′ UTR.
The candidate cDNAs predict a human MCCα of 725
amino acids with a calculated molecular mass of 80
kDa, a mouse MCCα of 717 amino acids with a calcu-
lated molecular mass of 79 kDa, and a human MCCβ
of 563 amino acids with a calculated molecular mass of
61 kDa. Human MCCα has 84% and 45% identity to
MCCα of mouse and A. thaliana, respectively (Figure
3a). Human MCCβ has 60% identity to MCCβ of A.
thaliana (Figure 3b). Similar to PCC, the MCCα subunit
contains an NH2-terminal biotin carboxylation domain
and a COOH-terminal biotin carrier domain (10). The
biotin carrier domain is centered on the motif AMKM,
which is found in most biotinylated proteins (Figure
3a) (10). Biotin is covalently attached to the ε-amino
group of lysine 681; the ε-biotinyl lysine amide is
termed biocytin (Figure 3a). As with other biotin-
dependent carboxylases, there is a conserved (A)PM
motif 29 residues NH2-terminal and a hydrophobic
residue (F714) 33-31 residues COOH-terminal of bio-
cytin (35). The biotin carboxylation domain is located
in the NH2-terminal two-thirds of MCCα and is linked
to the biotin carrier domain by a less-conserved (only
25% identity to A. thaliana residues 427-664) “hinge”
region of residues 441-650. Additionally, there is per-
fect conservation of 11 residues (Figure 3a, asterisks)
that are highly conserved among all biotin-dependent
Figure 2
Expression of the biotin-containing MCCα subunit in fibroblasts.
Proteins in mitochondrial enriched fractions from cultured fibrob-
lasts were separated by SDS-PAGE, and the biotin-containing sub-
units of MCC, PCC, and PC were detected with an avidin alkaline
phosphatase conjugate. Most, but not all, CG2-probands lack the
MCCα subunit, while it is detectable in all CG1 probands.
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Figure 3
Sequence alignment of human
MCCα and MCCβ with orthologs
from mouse and A. thaliana. Amino
acids identical to the human
sequence are highlighted. Missense
mutations identified in MCC-defi-
cient patients are indicated above
with the substituted amino acid.
Potential cleavage sites for the
NH2-terminal mitochondrial leader
sequences are indicated by vertical
arrowheads. (a) Sequence align-
ment of human, mouse, and A.
thaliana MCCα. The predicted ATP-
binding site in the NH2-terminal
biotin carboxylation domain and
the predicted COOH-terminal
biotin carboxyl carrier domain are
indicated by solid and dashed over-
lines, respectively. The arrow indi-
cates the lysine residue that links
covalently to biotin (biocytin). The
residues marked with an asterisk
within the biotin carboxylation
domain are thought to play an
important role in catalysis (36,
37). (b) Sequence alignment of
human and A. thaliana MCCβ. The
putative 3-methylcrotonyl-CoA
binding domain is indicated by a
solid over-line.
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Figure 4
Coomassie-stained SDS-PAGE gel of biotin-containing proteins puri-
fied from a mouse kidney extract with streptavidin Dynabeads. We
excised the proteins from the gel, digested with trypsin, and analyzed
the tryptic peptides using MALDI-TOF and liquid chromatography
coupled to ESI-MS/MS. We analyzed all the indicated bands includ-
ing those that we identified as MCCα and β.
carboxylases and thought to play a role in catalysis (12,
36, 37). Consistent with this prediction, the putative
carboxylation domain contains the conserved sequence
GGGGKGMRIV at positions 209-218 (Figure 3a),
which is part of the ATP binding pocket in the biotin
carboxylation domain of Escherichia coli ACC (37) and is
similar to a consensus P-loop ATP-binding site
[G′XGK(TS)] (38). The β subunit has a putative CoA
binding motif (Figure 3b) (10, 39).
MCCα and β have candidate NH2-terminal mito-
chondrial targeting sequences with multiple arginine
residues and a paucity of acidic residues (40). Possible
cleavage sites are indicated by vertical arrowheads in
Figure 3. Because the sequence of mitochondrial lead-
ers is not highly conserved, we favor the more COOH-
terminal cleavage site in MCCα just before a highly
conserved region (Figure 3a).
Isolation and mass spectrometry analysis of biotin-contain-
ing proteins. We also used a biochemical strategy to
identify MCCα and β. We enriched biotin-containing
proteins in a mouse kidney extract using streptavidin
Dynabeads and separated these by SDS-PAGE (Figure
4). Using MALDI-TOF and electrospray ionization
mass spectrometry (ESI-MS/MS), we analyzed tryptic
fragments of these proteins to confirm the identity
expected on the basis of the size of ACC, PC, and
PCCβ. The analysis of the expected PCCα identified,
in addition to fragments derived from PCCα, unique
fragments corresponding to the conceptual transla-
tion of the putative murine MCCA cDNA (Figure 4).
We identified 35 peptides with 100% identity to the
putative murine MCCα subunit covering 571 amino
acids or 80% of the putative full-length murine MCCα.
The protein comigrating with the 66-kDa marker (Fig-
ure 4) contained tryptic fragments with sequences cor-
responding to the conceptual translation of the puta-
tive human MCCB cDNA. We identified 25 peptides
with 100% identity to the putative human MCCβ sub-
unit covering 414 amino acids or 74% of the putative
full-length MCCβ. These sequence results strongly
supported the identity of the mammalian MCCA and
MCCB cDNAs.
Organization of human MCCA
and MCCB structural genes
During the course of determining the structural
organization of these genes by long-range PCR and
direct sequencing, we identified sequences correspon-
ding to MCCA and MCCB in the human high through-
out genome sequence database (GenBank accession
numbers AC026920 and AC026775, respectively).
These clones contain exons encoding the complete
MCCA and MCCB cDNAs and provide all exon/intron
boundaries including the flanking intronic sequences
with one exception (5′ flanking intronic sequence of
MCCA exon 8). MCCA has 19 exons and MCCB 17
exons. Given that the draft sequence has gaps, our
information on the size of some introns is incomplete.
Because the MCCA gene was not mapped in the Uni-
Gene database, we searched the flanking sequence in
the BAC clone containing MCCA for other mapped
genes. We identified the UniGene cluster Hs.10887
represented by several ESTs present in the MCCA
genomic clone and localized to 3q25-q27 (D3S1553-
D3S1580). To confirm this localization, we used the
Genebridge 4 radiation hybrid panel to regionally
localize MCCA 3.56 cR from the WI-6365 marker cor-
responding to the same region on chromosome 3.
Similarly, we identified UniGene cluster Hs.167531
representing several EST clones covering the 3′ end of
the MCCB cDNA. This cluster maps to chromosome
5q12-q13.1 (D5S637-D5S1977).
Patients with isolated MCC deficiency have
mutations in MCCA or MCCB
To confirm the identity of MCCA and MCCB, we sur-
veyed these genes for mutations in our collection of 14
unrelated MCC-deficient probands. We grouped the
probands according to their CGs and used RT-PCR to
amplify the corresponding mRNA from their cultured
skin fibroblasts. We sequenced the entire ORF in each
proband and confirmed all mutations by direct
sequencing of PCR-amplified genomic DNA. In two
additional probands (015 and 016) (ref. 4) from the
Amish/Mennonite population in Lancaster County,
Pennsylvania, we searched for mutations by direct
sequencing of PCR-amplified genomic DNA. We iden-
tified five MCCA mutant alleles in CG2 cell lines
accounting for ten of 12 possible mutant MCCA genes
(Table 1). The mutations include three uncomplicated
missense mutations (Figure 3a), one missense mutation
that alters splicing (Figure 5a), and one 1-bp insertion.
In CG1 cell lines, we identified nine MCCB mutant alle-
les accounting for 12 of 16 possible mutant genes (Table
2). The mutations include 6 uncomplicated missense
mutations (Figure 3b), one missense mutation that
alters splicing (Figure 5b), one splice site mutation, and
one 1-bp insertion. In spite of sequencing all exons and
flanking intronic sequences (with the exception of the
alleles has a low frequency in this population. We did
not screen for alleles for which we did not have the
appropriate control population (Vietnamese, MCCB-
R155Q, -P310R; Turkish, MCCB-S173L, -V339M).
Discussion
Using a combination of homology probing and mass
spectrometry we cloned human MCCA and MCCB full
length cDNAs. The conceptual translation of MCCA
shows the expected NH2-terminal biotin carboxylation
domain and the COOH-terminal biotin carboxyl carrier
domain (Figure 3a), separated by a less conserved
“hinge” region (10, 12). Presumably because of differ-
ences in substrate specificities, carboxyltransferase
domains are less conserved among biotin-dependent
carboxylases. MCC catalyzes the carboxylation of
methylcrotonyl-CoA (1). The acceptor binding site is
thought to be on MCCβ (10, 39). Consistent with this,
human MCCβ shares high identity with A. thaliana
MCCβ (60%) and only 28% identity with human PCCβ
(13) that supports the role of the β subunit in determin-
ing substrate specificity of these enzymes (Figure 3b).
Our series of 6 MCCA- and 10 MCCB-deficient
5′ flanking intronic sequence of
MCCA exon 8), we were not able to
identify a second allele in two CG2
and four CG1 probands. In five of
these probands, the one allele identi-
fied appeared to be homozygous in
the RT-PCR product, but was clearly
heterozygous in genomic DNA, sug-
gesting that the steady level of
mRNA from the second allele was
not detectable as would be the case
for a promoter mutation or an intra-
genic deletion or insertion missed by
genomic PCR. These results strong-
ly support the identification of the
MCCA and MCCB genes and their
assignment to MCC deficiency in
CG2 and CG1, respectively.
Expression of MCCA
and MCCB alleles
As a final test of the identity of our
candidate human MCCA and
MCCB cDNAs, we subcloned them
into a mammalian expression vector
(pTracer-CMV2), electroporated the
recombinant constructs into a
SV40T transformed reference CG2
or CG1 cell line, and measured MCC
activity 72 hours later (27). As a ref-
erence, we also measured PCC activ-
ity (27). Wild-type MCCA and MCCB
alleles restored MCC activity to 43%
and 53% of untransfected control
fibroblasts, respectively (Table 3).
Transfection efficiency, assessed by
scoring a subset of cells in each transfection for the
presence of the coexpressed GFP, ranged from 10 to
20% in these experiments.
Similarly, to test the functional consequences of the
missense mutations, we expressed three MCCA and six
MCCB missense alleles. MCCB-R193C and -V339M had
activity of 6 and 7 pmol/min/mg protein, respectively,
or about 4% of the activity produced by the wild-type
allele, whereas the remaining four MCCB alleles and the
three MCCA alleles produced no detectable activity
(Table 3). These results confirm the deleterious func-
tional consequences of the tested missense mutations.
Population frequency of selected MCCA
and MCCB alleles
Additionally, we used allele-specific oligonucleotide
analysis (34) to survey a North American control popu-
lation of 66 individuals for three MCCA alleles (R385S,
A289V, and L437P) and two MCCB alleles (E99Q and
R193C). Aside from one individual heterozygous for
R385S, we did not identify any of these alleles in this
collection of 132 control chromosomes (data not
shown). These results indicate that each of these mutant
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Figure 5
MCCA and B missense mutations that alter splicing. (a) MCCA D532H. The 1594G→C trans-
version of the last bp of exon 13 results in the missense mutation D532H. The 3′ base of an
exon also contributes to donor splice site recognition and, as shown in the lower panel, RT-PCR
of MCCA cDNA in this patient with primers corresponding to the 5′ and 3′ UTR resulted in a
product smaller than in wild-type. Sequence analysis of this product showed that exon 13 (217
bp) is skipped, which shifts the reading frame. Thus, the deleterious consequences of this mis-
sense mutation appear to be entirely due to the splicing defect. (b) MCCB I437V. As shown in
the upper panel, the 1309A→G transition in exon 14 results in the replacement of isoleucine
by valine, a conservative change. However, the mutation also activates a cryptic splice donor.
Use of this new donor splice site deletes the last 64 bp of exon 14 from the mature transcript.
As shown in the lower panel, direct sequencing of the RT-PCR product shows that virtually all
the transcript present uses the new, more 5′ splice donor. The second allele of this compound
heterozygous patient does not produce detectable RNA. wt, wild-type; mut, mutant.
502 The Journal of Clinical Investigation | February 2001 | Volume 107 | Number 4
probands is characterized by the fact that almost every
proband had a unique genotype with no prevalent
mutant allele for either gene. In agreement with this
observation, using allele-specific oligonucleotide analy-
sis to screen 66 North American controls (132 chro-
mosomes), we found only a single heterozygote from
one allele (MCCA-R385S) and no carriers for the others
tested (MCCA-A289V, -L437P; MCCB-E99Q, -R193C).
For MCCA, we assume functional significance for the
frameshift mutation Q421fs(+1) and the missense
mutation D532H, which alters splicing (Figure 5a),
because both result in truncated proteins lacking func-
tionally important domains. The MCCA mutations
R385S, A289V, and L437P all change conserved
residues (Figure 3a), and the corresponding alleles con-
fer no detectable MCC activity when expressed in the
CG2 reference cell line (Table 3). In contrast to the
other four CG2 probands tested, who had no
detectable MCCα, we detected normal amounts of
MCCα protein in the proband 011 homozygous for
R385S (Figure 2). This result is consistent with the pre-
diction based on the structure of the biotin carboxyla-
tion domain of E. coli ACC that the residue correspon-
ding to MCCα R385 is part of a positively charged
pocket for bicarbonate binding (36, 37).
For MCCB, we assume functional significance for the
frameshift mutation S173fs(+1), the splice site muta-
tion In5ac-1G→A and the missense mutation I437V,
which alters splicing (Figure 5b). The
remaining six MCCB missense mutations all
change conserved residues and were the
only coding alterations we found in
sequencing the full-length ORF (Figure 3b).
In expression studies, we showed that the
MCCB-R155Q, -P310R, -S173L, and -E99Q
alleles had no detectable MCC activity,
whereas MCCB-V339M and -R193C had
some residual activity, about 4% of the
experimental control value (Table 3), when
expressed in CG1-deficient reference cell
lines. We identified V339M in two com-
pound heterozygous Turkish probands
(Table 2), the only patients in our collection
with residual MCC activity in fibroblasts.
Although 4% residual activity is at the detec-
tion limit of the standard MCC assay we used
for the expression studies (27), these results are
in accordance with the residual activity detect-
ed in fibroblasts of these patients with a modi-
fied MCC assay of increased sensitivity (3, 22).
MCCα was reduced, but clearly present, in all
CG1 cell lines in our biochemical detection of
the biotin-containing α subunit (Figure 2).
This suggests that the MCCα subunit is less
stable when the β subunit is absent or defective.
Interestingly, we detected the MCCβ
S173fs(+1), a T insertion, as one allele in a mild-
ly affected Swiss compound heterozygote (20)
and in an asymptomatic Mennonite homozy-
gote from Lancaster County, Pennsylvania (Table 2).
The ancestors of the Lancaster County Amish/Men-
nonite population originated from Switzerland (41)
and may have brought this allele with them. Haplotype
analysis will be necessary to confirm a founder muta-
tion. Moreover, the Amish proband is homozygous for
a different MCCB allele, E99Q. Thus, despite the small
size and common origins of the Amish/Mennonite
population in this region, there is allelic heterogeneity
for MCC deficiency.
Combining our results and the published clinical
reports (2–4, 19–25), we were not able to discern a
phenotype-genotype correlation. Probands 010 and
015, homozygous for truncating mutations in MCCA
or MCCB (Tables 1 and 2), have, in one case, no symp-
toms and, in the other, a mild phenotype with late
onset and no residual damage (23). By contrast,
probands 011, 001, and 002, homozygous for mis-
sense mutations MCCA-R385S, MCCB-S173L, and -
E99Q, have a severe phenotype with early-onset,
major neurological involvement and, in one case, a
fatal outcome (Table 1) (2, 3, 24). Proband 016, an
adult Amish patient homozygous for the same
MCCB-E99Q, has only mild symptoms (4). Further-
more, the two Turkish patients with MCCB-V339M
that have some residual MCC activity both have a
severe phenotype. Taken together, these results sug-
gest that factors other than the genotype at the
Table 2
MCCB mutant alleles
No. Allele Exon Nucleotide Clinical Ethnic Proband
change phenotypeA origin
1 R155Q 5 464G→A Mild Vietnamese 006
2 P310R 10 929C→G Mild Vietnamese 006
3 S173fs(+1) 6 518insT Mild Swiss/MennoniteB 004C, 015D
4 I437V 14 1309A→GE Mild Dutch 003C
5 R193C 6 577C→T Mild Dutch 005
6 In5ac-1G→A In5ac-1G→A Mild Dutch 005
7 S173L 6 518C→T Severe Turkish 001D
8 E99Q 4 295G→C Severe/mild Turkish/Amish 002D, 016D
9 V339M 11 1015G→A Severe Turkish 007C, 008C
AMild: late onset, good recovery after acute attack, no or mild developmental delay; severe:
onset in infancy, severe neurological involvement with severe developmental delay. BDetect-
ed by newborn screening. COnly one allele identified. DHomozygous. EActivates cryptic splice
donor (Figure 5b).
Table 1
MCCA mutant alleles
No. Allele Exon Nucleotide Clinical Ethnic Proband
change phenotypeA origin
1 R385S 11 1155A→C Severe German 011B
2 Q421fs(+1) 11 1264insG Mild Swedish/Amer. 013C, 010B
3 A289V 8 866C→T Mild American 012C
4 D532H 13 1594G→CD Severe Turkish 009B
5 L437P 12 1310T→C Severe Argentine 014B
AMild: late onset, good recovery after acute attack, no or mild developmental delay;
severe: onset in infancy, severe neurological involvement with severe developmental delay.
BHomozygous. COnly one allele identified. DAlters splicing (Figure 5a).
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MCCA and MCCB loci (modifying genes, environ-
mental variables) must have a major influence on the
phenotype of MCC deficiency.
Since the widespread introduction of MS/MS to new-
born screening, many new patients with MCC defi-
ciency have been detected. Surprisingly, MCC deficien-
cy appears to be the most frequent organic aciduria in
these screening programs (4, 6–9) with an overall fre-
quency of approximately 1 in 50,000. Studies of these
prospectively identified individuals should provide
insight into the factors that determine the phenotypic
severity of MCC deficiency.
Note added in proof. We have recently learned that the
molecular basis of MCC deficiency has also been identi-
fied by Gallardo et al. (2001, Am. J. Hum. Genet. 68:334).
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